Idiopathic Pulmonary Fibrosis (IPF) Market Size
The Global Idiopathic Pulmonary Fibrosis Market size reached US$ 2,184.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 4,614.3 million by 2030. The global idiopathic pulmonary fibrosis market is expected to exhibit a CAGR of 10.1% during the forecast period (2024-2031). The key market trend is the increasing demand for strong pipeline drugs.
The key market trend is the increasing demand for strong pipeline drugs.
For instance, in May 2023, GRI Bio, Inc., a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic, and autoimmune diseases, announced a business outlook and highlighted upcoming milestones for its innovative pipeline of NKT cell modulators in development.
Idiopathic Pulmonary Fibrosis (IPF) is a chronic and progressive lung disease characterized by the scarring and thickening of the lung tissue. It is called idiopathic because the exact cause of the condition is unknown. IPF affects the ability of the lungs to function properly, leading to symptoms such as persistent cough, shortness of breath, fatigue, and ultimately respiratory failure. It usually affects people around 70 to 75 years old and is rare in people under 50.
The global idiopathic pulmonary fibrosis market is driven by factors such as the increasing clinical trials of IPF drugs, the rising aging population, the availability of approved therapies, the growing pipeline and investigational drugs, rising awareness & early diagnosis, and advancements in research techniques.
For instance, in February 2023, Daewoong Pharmaceutical, a South Korean pharmaceutical company, announced that the first participant has been administered in the Phase II clinical trial of Bersiporocin to treat idiopathic pulmonary fibrosis. The multinational Phase II clinical trial has been designed for assessing Bersiporocin’s safety and efficacy in changing the improvement rate of forced vital capacity (FVC) after receiving Bersiporocin or a placebo for 24 weeks.
Market Scope
| Metrics | Details |
| CAGR | 10.1% |
| Size Available for Years | 2021-2030 |
| Forecast Period | 2024-2031 |
| Data Availability | Value (US$) |
| Segments Covered | Treatment, End-User, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
To know more Insights Download Sample
Market Dynamics
Availability of Approved Therapies
The availability of approved therapies for the treatment of idiopathic pulmonary fibrosis is the major factor driving the market share during the forecast period. The approval of antifibrotic medications, such as pirfenidone and nintedanib, demonstrated efficacy in slowing disease progression and improving patient outcomes. The availability of approved therapies has not only provided treatment options but also increased the overall interest and investment in IPF research and development.
For instance, in May 2022, the U.S. Food and Drug Administration (FDA) granted permission for Angion Biomedica, a clinical-stage biopharmaceutical company, to launch a Phase clinical 1b trial to test its experimental anti-fibrotic medication ANG-3070 in people with idiopathic pulmonary fibrosis (IPF).
Limited Treatment Options and Side Effects of the Treatment
The side effects of the treatment and the limited treatment options associated with idiopathic pulmonary fibrosis are the major factors expected to hamper the market growth. Despite the availability of approved therapies, the treatment options for IPF are still limited. Antifibrotic drugs, such as pirfenidone and nintedanib, are the mainstay of treatment, but they are not curative and only slow disease progression, which can limit the treatment options for patients.
While antifibrotic drugs have shown efficacy, they can be associated with adverse effects that may impact patient tolerability and treatment adherence. Gastrointestinal symptoms, skin reactions, and liver function abnormalities are among the potential side effects associated with these medications. The occurrence of adverse effects can limit the use of these drugs in certain patients or require close monitoring and management, affecting their overall acceptance.
Market Segment Analysis
The global idiopathic pulmonary fibrosis market is segmented based on treatment, end-user, and region.
Based on Treatment, the Drugs Segment is Expected to Dominate the Market Share
The market for drugs segment holds the 45.3% of the global idiopathic pulmonary fibrosis market share in 2022. The drugs segment includes pharmaceutical interventions for IPF, such as antifibrotic medications and potential future therapies.
Antifibrotic drugs, such as pirfenidone and nintedanib, have gained wide acceptance and are considered the standard of care for IPF. These medications have been extensively studied in clinical trials and have been shown to slow the decline in lung function and prolong survival. The high adoption of antifibrotic medications by healthcare professionals contributes to the dominance of the drugs segment.
Source: DataM Intelligence Analysis (2023)
Market Geographical Share
North America Holds the Largest Market Share Due to the High Disease Burden and Availability of Approved Therapies
North America holds the 40.2% market share for the idiopathic pulmonary fibrosis market in 2022 due to the high disease burden and availability of approved therapies. North America has a relatively high prevalence of IPF compared to other regions. The aging population, environmental factors, and genetic predisposition contribute to the increased disease burden in this region.
The United States was one of the first countries to approve antifibrotic drugs, such as pirfenidone and nintedanib, for the treatment of IPF. These medications have been widely adopted in North America and are considered the standard of care. The availability of approved therapies contributes to the market dominance in this region.
Source: DataM Intelligence Analysis (2023)
Idiopathic Pulmonary Fibrosis (IPF) Companies
The major global players include Roche Holdings AG, Boehringer Ingelheim GmbH, Genentech Inc., FibroGen Inc., Galapagos NV, MEDICINOVA INC., Bristol Myers Squibb Company, Biogen Inc., AstraZeneca PLC, and Novartis International AG.
COVID-19 Impact on Market
The COVID-19 pandemic has had a significant impact on the idiopathic pulmonary fibrosis market. COVID-19 primarily affects the respiratory system, and individuals with pre-existing lung conditions, including IPF, are at a higher risk of developing severe illness if they contract the virus. The heightened vulnerability of IPF patients to COVID-19 has led to increased attention to their care, management, and protection.
The COVID-19 pandemic highlighted the importance of respiratory health and increased awareness about lung diseases, including IPF. This heightened focus on respiratory health may drive attention, research, and funding towards IPF and other pulmonary fibrosis conditions.
Russia-Ukraine Conflict Analysis
The Russia-Ukraine war significantly impacted the idiopathic pulmonary fibrosis market growth. The conflict may affect international collaborations and research initiatives involving Russian and Ukrainian healthcare institutions, pharmaceutical companies, and academic organizations.
Collaboration and exchange of scientific knowledge are crucial for advancing IPF research and developing new therapies. Political tensions and restrictions on collaboration can impede progress and hinder the exchange of expertise and resources leading to a negative impact on the idiopathic pulmonary fibrosis market globally.
Key Developments
- In May 2023, Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug Application (IND) for a Phase II study in patients with Idiopathic Pulmonary Fibrosis, the most common form of progressive fibrosing interstitial lung disease. As a result, Cumberland will launch its FIGHTING FIBROSIS trial designed to enroll 128 patients in over 20 medical centers of excellence across the U.S.
- In May 2023, Simulations Plus, Inc., a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, announced the release of a new integrated pulmonary software and services package. This targeted package will support pharmaceutical companies by streamlining their pulmonary drug development processes, enabling them to make better-informed decisions and bring therapies to market faster.
Why Purchase the Report?
- To visualize the global idiopathic pulmonary fibrosis market segmentation based on treatment, end-user, and region and understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of idiopathic pulmonary fibrosis market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global idiopathic pulmonary fibrosis market report would provide approximately 54 tables, 46 figures, and 195 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
